Biotech Values

[DewDiligence]

Telaprevir and/or Boceprevir ought to be approved in China by the end of 2012; thus, by the 2021 date we’ve been discussing in this thread, these drugs will have had nine years to reduce the addressable patient pool with chronic HCV infection.

In short, I would say the big business opportunity for HCV drugs—Asia included—will come during the next 10 years, not in the decades thereafter.